HRP20211353T1 - Postupci za ekspanziju ili depleciju regulacijskih t-stanica - Google Patents
Postupci za ekspanziju ili depleciju regulacijskih t-stanica Download PDFInfo
- Publication number
- HRP20211353T1 HRP20211353T1 HRP20211353TT HRP20211353T HRP20211353T1 HR P20211353 T1 HRP20211353 T1 HR P20211353T1 HR P20211353T T HRP20211353T T HR P20211353TT HR P20211353 T HRP20211353 T HR P20211353T HR P20211353 T1 HRP20211353 T1 HR P20211353T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- antibody
- antigen
- preparation
- binding fragment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 5
- 210000003289 regulatory T cell Anatomy 0.000 title claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 210000004698 lymphocyte Anatomy 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 2
- 208000021309 Germ cell tumor Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000031888 Mycoses Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 2
- 206010046431 Urethral cancer Diseases 0.000 claims 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000005969 Uveal melanoma Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 201000007983 brain glioma Diseases 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 201000002143 bronchus adenoma Diseases 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 208000002458 carcinoid tumor Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 201000000292 clear cell sarcoma Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 208000037828 epithelial carcinoma Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 230000002267 hypothalamic effect Effects 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 201000002575 ocular melanoma Diseases 0.000 claims 2
- 208000022982 optic pathway glioma Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 201000002511 pituitary cancer Diseases 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 210000002435 tendon Anatomy 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000037965 uterine sarcoma Diseases 0.000 claims 2
- 206010046885 vaginal cancer Diseases 0.000 claims 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Claims (10)
1. Izolirano humanizirano, humano ili himerično protutijelo ili njegov fragment koji veže antigen, koji se selektivno veže na epitop iz TNFR2 unutar aminokiselina 130-149 iz SEQ ID NO: 1, navedeno protutijelo ili njegov fragment koji veže antigen koji ima antagonistički učinak na TNFR2 nakon vezanja.
2. Protutijelo ili njegov fragment koji veže antigen u skladu s patentnim zahtjevom 1, naznačeno time da navedeno protutijelo ili njegov fragment koji veže antigen:
a) veže se na epitop koji sadrži aminokiseline 135-147 iz SEQ ID NO: 1;
b) veže se na epitop koji sadrži aminokiseline 135-142 iz SEQ ID NO: 1;
c) odabrano je iz skupine koju čine monoklonsko protutijelo ili njegov fragment koji veže antigen, poliklonsko protutijelo ili njegov fragment koji veže antigen, Fab, bispecifično protutijelo ili njegov fragment koji veže antigen, njegovo monovalentno protutijelo ili njegov fragment koji veže antigen, jednolančana Fv-molekula, bispecifična jednolančana Fv ((scFv’)2), protutijelo domene, diatijelo, triatijelo, srodno tijelo, protutijelo domene, SMIP, nanotijelo, Fv-fragment, Fab-fragment, molekula F(ab’)2 i tandemski fragment scFv (taFv); ili
d) pokazuje ravnotežnu konstantu disocijacije („KD”) manju od oko 50 nM, manju od oko 10 nM ili manju od oko 1 nM.
3. Protutijelo ili njegov fragment koji veže antigen u skladu s patentnim zahtjevom 1 ili 2, naznačeno time da je namijenjeno uporabi u liječenju proliferativnog poremećaja ili zarazne bolesti kod pacijenta.
4. Protutijelo ili njegov fragment koji veže antigen u skladu s patentnim zahtjevom 1 ili 2, naznačeno time da je namijenjeno uporabi prema patentnom zahtjevu 3, gdje:
a) je spomenuti proliferativni poremećaj rak odabran iz skupine koju čine akutna limfoblastna leukemija, akutna mijeloična leukemija, adrenokortikalni karcinom, limfom povezan s AIDS-om, maligni tumori povezani s AIDS-om, karcinom mjehura, rak kostiju / zloćudni vlaknasti histiocitom, gliom moždanog debla, gliom optičkog puta i gliom hipotalamusa, rak dojke, bronhijalni adenomi / karcinoidi, kronična limfocitna leukemija, kronična mijelogena leukemija, kronični mijeloproliferativni poremećaji, sarkom čistih stanica omotača tetiva, rak debelog crijeva, kolorektalni karcinom, kožni T-stanični limfom, rak endometrija, epitelni karcinom, rak jednjaka, tumori iz obitelji Ewingovog sarkoma, ekstrakranijalni tumor zametnih stanica, ekstragonadalni tumor zametnih stanica, rak ekstrahepatičnog žučnog kanala, rak oka, intraokularni melanom, retinoblastom, rak žučnog mjehura, rak želuca, leukemija dlakavih stanica, rak glave i vrata, hepatocelularni karcinom (jetre), Hodgkinov limfom, rak hipofaringeusa, Kaposijev sarkom, rak bubrega, rak grkljana, rak hipofize, multipli mijelom / rak neoplazma stanica, pleuropulmonalni blastom, rak kože, rak pluća malih stanica, rak tankog crijeva, sarkom mekih tkiva, karcinom skvamoznih stanica vrata, rak testisa, rak štitnjače, rak uretre, sarkom maternice i rak rodnice, ili je solidni tumor mozga, pluća, dojke, limfoida, gastrointestinalnog trakta, genitourinarnog trakta, ždrijela, prostate ili jajnika; ili
b) spomenuta zarazna bolest odabrana je iz skupine koju čine bakterijska infekcija, virusna infekcija, gljivična infekcija i parazitska infekcija.
5. Postupak za proizvodnju pripravka obogaćenog limfocitima, naznačen time da obuhvaća in vitro kontaktiranje populacije ljudskih stanica koja sadrži navedene limfocite dobivene iz uzorka ljudske krvi ili koštane srži od pacijenta s protutijelom ili njegovim fragmentom koji veže antigen, u skladu s patentnim zahtjevom 1 ili 2, čime se proizvodi navedeni pripravak obogaćen limfocitima, pri čemu navedene Treg stanice čine manje od 10 % stanica u navedenom pripravku.
6. Postupak prema patentnom zahtjevu 5, naznačen time da:
a) spomenuti postupak nadalje uključuje izolaciju navedenih ljudskih stanica iz uzorka ljudske krvi ili uzorka ljudske koštane srži prije navedenog kontakta; ili
b) navedene Treg stanice čine manje od 5 % stanica u navedenom pripravku.
7. Pripravak proizveden postupkom prema patentnim zahtjevima 5 ili 6, naznačen time da je navedeni pripravak obogaćen limfocitima i da Treg stanice u navedenom pripravku čine manje od 10 % stanica u navedenom pripravku.
8. Pripravak prema patentnom zahtjevu 7, naznačen time da navedene Treg stanice čine manje od 5 % stanica u navedenom pripravku.
9. Pripravak prema patentnom zahtjevu 7 ili 8, naznačen time da je namijenjen uporabi u liječenju proliferativnog poremećaja ili zarazne bolesti kod pacijenata.
10. Pripravak za uporabu prema patentnom zahtjevu 9, naznačen time da:
a) je spomenuti proliferativni poremećaj rak odabran iz skupine koju čine akutna limfoblastna leukemija, akutna mijeloična leukemija, adrenokortikalni karcinom, limfom povezan s AIDS-om, maligni tumori povezani s AIDS-om, karcinom mjehura, rak kostiju / zloćudni vlaknasti histiocitom, gliom moždanog debla, gliom optičkog puta i gliom hipotalamusa, rak dojke, bronhijalni adenomi / karcinoidi, kronična limfocitna leukemija, kronična mijelogena leukemija, kronični mijeloproliferativni poremećaji, sarkom čistih stanica omotača tetiva, rak debelog crijeva, kolorektalni karcinom, kožni T-stanični limfom, rak endometrija, epitelni karcinom, rak jednjaka, tumori iz obitelji Ewingovog sarkoma, ekstrakranijalni tumor zametnih stanica, ekstragonadalni tumor zametnih stanica, rak ekstrahepatičnog žučnog kanala, rak oka, intraokularni melanom, retinoblastom, rak žučnog mjehura, rak želuca, leukemija dlakavih stanica, rak glave i vrata, hepatocelularni karcinom (jetre), Hodgkinov limfom, rak hipofaringeusa, Kaposijev sarkom, rak bubrega, rak grkljana, rak hipofize, multipli mijelom / rak neoplazma stanica, pleuropulmonalni blastom, rak kože, rak pluća malih stanica, rak tankog crijeva, sarkom mekih tkiva, karcinom skvamoznih stanica vrata, rak testisa, rak štitnjače, rak uretre, sarkom maternice i rak rodnice, ili je solidni tumor mozga, pluća, dojke, limfoida, gastrointestinalnog trakta, genitourinarnog trakta, ždrijela, prostate ili jajnika; ili
b) spomenuta zarazna bolest odabrana je iz skupine koju čine bakterijska infekcija, virusna infekcija, gljivična infekcija i parazitska infekcija.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361762136P | 2013-02-07 | 2013-02-07 | |
US201361763217P | 2013-02-11 | 2013-02-11 | |
EP14748807.6A EP2953634B1 (en) | 2013-02-07 | 2014-02-06 | Methods for expansion or depletion of t-regulatory cells |
PCT/US2014/015101 WO2014124134A1 (en) | 2013-02-07 | 2014-02-06 | Methods for expansion or depletion of t-regulatory cells |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211353T1 true HRP20211353T1 (hr) | 2021-11-26 |
Family
ID=51300130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211353TT HRP20211353T1 (hr) | 2013-02-07 | 2021-08-25 | Postupci za ekspanziju ili depleciju regulacijskih t-stanica |
Country Status (9)
Country | Link |
---|---|
US (4) | US9821010B2 (hr) |
EP (2) | EP3936137A1 (hr) |
JP (4) | JP6367836B2 (hr) |
DK (1) | DK2953634T3 (hr) |
ES (1) | ES2885423T3 (hr) |
HR (1) | HRP20211353T1 (hr) |
PL (1) | PL2953634T3 (hr) |
PT (1) | PT2953634T (hr) |
WO (1) | WO2014124134A1 (hr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6031552A (en) * | 1994-11-18 | 2000-02-29 | Heidelberger Druckmaschinen Ag | Printing device with patterned recording surface |
EP3936137A1 (en) | 2013-02-07 | 2022-01-12 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
AU2016226414B2 (en) * | 2015-03-02 | 2021-09-09 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an IL-33 antagonist |
AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
AU2016263198C1 (en) | 2015-05-15 | 2023-10-05 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
WO2017040312A1 (en) * | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
US11266730B2 (en) | 2015-09-29 | 2022-03-08 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for BCG therapy |
CA3003334A1 (en) * | 2015-10-28 | 2017-05-04 | Life Technologies As | Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio |
WO2017083525A1 (en) * | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
IL259576B (en) | 2015-12-04 | 2022-09-01 | Novartis Ag | grna molecule containing tracr and crrna, pharmaceutical composition containing it and method for preparing cells for immunotherapy |
WO2017123550A1 (en) * | 2016-01-11 | 2017-07-20 | Autotelic Llc | Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension |
KR20240095471A (ko) * | 2016-05-13 | 2024-06-25 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
US11359027B2 (en) | 2016-06-22 | 2022-06-14 | Universite Paris Est Creteil Val De Marne | Prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist |
JP7054209B2 (ja) * | 2016-11-21 | 2022-04-13 | 国立研究開発法人医薬基盤・健康・栄養研究所 | エピトープ均質化抗体パネル、ならびにその作製方法および利用 |
CA3056406A1 (en) | 2017-03-15 | 2018-09-20 | Orca Biosystems Inc. | Compositions and methods for hematopoietic stem cell transplants |
EP3601561A2 (en) | 2017-03-22 | 2020-02-05 | Novartis AG | Compositions and methods for immunooncology |
AU2018268970A1 (en) | 2017-05-19 | 2019-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfr2 for cancer immunotherapy |
EP3710019A1 (en) * | 2017-11-14 | 2020-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Regulatory t cells genetically modified for the lymphotoxin alpha gene and uses thereof |
US20210393700A1 (en) * | 2017-11-29 | 2021-12-23 | Figene, Llc | Interaction of fibroblasts and immune cells for activation and uses thereof |
CN113056487A (zh) * | 2018-09-18 | 2021-06-29 | 梅里麦克制药股份有限公司 | 抗tnfr2抗体及其用途 |
CA3117756A1 (en) * | 2018-11-01 | 2020-05-07 | Bioinvent International Ab | Novel agonistic antibody molecules |
US20220073634A1 (en) * | 2018-11-01 | 2022-03-10 | Bioinvent International Ab | Novel agonistic anti tnfr2 antibody molecules |
CN109609616B (zh) * | 2018-11-05 | 2021-12-07 | 复旦大学附属华山医院 | Hla-a*02:01和hla-c*01:02在丹参酮所致药疹中的用途 |
US20220002423A1 (en) * | 2018-11-15 | 2022-01-06 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
EP3930846A1 (en) * | 2019-03-01 | 2022-01-05 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
CN109846863B (zh) * | 2019-03-12 | 2021-09-21 | 成都金瑞基业生物科技有限公司 | 和厚朴酚的用途 |
CN110179790A (zh) * | 2019-07-02 | 2019-08-30 | 广西医科大学 | 一种抑制肝星状细胞活化药物的制备及应用 |
CN114641311A (zh) * | 2019-09-17 | 2022-06-17 | 埃派斯进有限公司 | 抗-tnfr2抗体及其使用方法 |
CN110693907A (zh) * | 2019-11-07 | 2020-01-17 | 南通大学 | 调节性T细胞在制备治疗或预防Zika病毒感染所致不良妊娠药物方面的应用 |
CN110974818A (zh) * | 2019-12-31 | 2020-04-10 | 中国药科大学 | 咖啡酸苯乙酯在制备肝再生药物中的应用 |
CN115996950A (zh) * | 2020-01-06 | 2023-04-21 | 高诚生物医药(香港)有限公司 | 抗tnfr2抗体和其用途 |
US20230192877A1 (en) * | 2020-03-30 | 2023-06-22 | National Institutes Of Biomedical Inovation, Health And Nutriton | Epitope region-bridging biparatopic antibody and method for producing same |
WO2021249542A1 (en) * | 2020-06-12 | 2021-12-16 | Nanjing Leads Biolabs Co., Ltd. | Antibodies binding tnfr2 and uses thereof |
EP4204094A1 (en) | 2020-08-27 | 2023-07-05 | Enosi Therapeutics Corporation | Methods and compositions to treat autoimmune diseases and cancer |
CN111920802B (zh) * | 2020-09-11 | 2024-01-23 | 华侨大学 | 穿心莲内酯在制备防治成人t细胞白血病药物的应用 |
CN115925929A (zh) | 2021-09-22 | 2023-04-07 | 上海康岱生物医药技术股份有限公司 | 抗tnfr2单克隆抗体及其应用 |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309418A (en) | 1980-03-25 | 1982-01-05 | Sloan-Kettering Research Institute For Cancer | Anti-tumor agent from human serum and process |
FR2513124B1 (fr) | 1981-07-21 | 1989-11-17 | Hayashibara Biochem Lab | Production et applications du facteur de lyse des cellules-cibles |
US4457916A (en) | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5288852A (en) | 1984-03-06 | 1994-02-22 | Dainippon Pharmaceutical Co., Ltd. | Human tumor necrosis factor polypeptides |
DE19975063I2 (de) | 1984-03-06 | 2005-08-18 | Dainippon Pharmaceutical Co | DNS den menschlichen Tumornekrosisfaktor kodierendund das menschliche Tumornekronisfaktor-Polypepti d. |
US4879226A (en) | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
DE3423234A1 (de) | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
GR851626B (hr) | 1984-07-05 | 1985-11-26 | Genentech Inc | |
AU589919B2 (en) | 1984-10-15 | 1989-10-26 | Cetus Corp | Human tumor necrosis factor |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4677064A (en) | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
DE3585690D1 (de) | 1984-12-21 | 1992-04-23 | Biogen Inc | Reinigung, herstellung und verwendung von tumor-nekrosisfaktoren. |
US4681760A (en) | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
US5059530A (en) | 1985-09-30 | 1991-10-22 | Suntory Ltd. | Expression vector for human TNF |
US6150090A (en) | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
ATE107362T1 (de) | 1986-06-20 | 1994-07-15 | Dainippon Pharmaceutical Co | Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns. |
US5002876A (en) | 1986-09-22 | 1991-03-26 | Phillips Petroleum Company | Yeast production of human tumor necrosis factor |
US4985241A (en) | 1986-11-21 | 1991-01-15 | Cetus Corporation | Therapeutic combination of free-radical scavenger and tumor necrosis factor |
US4963354A (en) | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
AU1346488A (en) | 1987-02-26 | 1988-09-26 | Cetus Corporation | Arginine-depleted human tumor necrosis factor |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5215743A (en) | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
JPH0797997B2 (ja) | 1988-04-28 | 1995-10-25 | 帝人株式会社 | 新規生理活性ポリペプチド |
US5370870A (en) | 1989-10-06 | 1994-12-06 | Genentech, Inc. | Method for protection against reactive oxygen species |
US5283058A (en) | 1990-08-30 | 1994-02-01 | The General Hospital Corporation | Methods for inhibiting rejection of transplanted tissue |
US5593698A (en) | 1990-10-31 | 1997-01-14 | Autoimmune, Inc. | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
CA2055168A1 (en) | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
DE69232798T2 (de) | 1991-08-02 | 2003-07-24 | Denise L Faustman | Diagnose und behandlung von autoimmunkrankheiten |
US6984380B1 (en) | 1991-08-02 | 2006-01-10 | Denise L. Faustman | Treatment of diseases involving faulty MHC class I antigen complex presentation |
US5139481A (en) | 1991-08-07 | 1992-08-18 | The General Hospital Corporation | Treatment for type II diabetes |
US5843425A (en) | 1992-02-19 | 1998-12-01 | The General Hospital Corporation | Transplantation and graft-versus-host-disease |
CZ283533B6 (cs) | 1992-04-02 | 1998-04-15 | F. Hoffmann-La Roche Ag | TNF - muteiny a způsob jejich výroby |
PT639979E (pt) | 1992-04-23 | 2002-03-28 | Sloan Kettering Inst Cancer | Ligando para o receptor c-kit e metodos para a sua utilizacao |
US5939532A (en) | 1993-09-07 | 1999-08-17 | Kyowa Hakko Kogyo Co., Ltd | Humanized antibodies to ganglioside GM2 |
WO1994009137A1 (en) | 1992-10-15 | 1994-04-28 | Genentech, Inc. | Antibodies against type 2 tumor necrosis factor receptor |
US5843452A (en) | 1992-11-09 | 1998-12-01 | Pharmagenesis, Inc. | Immunotherapy composition and method |
US5560908A (en) | 1993-01-22 | 1996-10-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Therapeutic agent for NIDDM |
JPH08510470A (ja) * | 1993-07-29 | 1996-11-05 | ハイジン,バーンハルト | Tリンパ球を含有する感染症治療用医薬組成物 |
US5728385A (en) | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
US5874301A (en) | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
AU7010996A (en) | 1995-08-30 | 1997-03-19 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Selective elimination of t cells that recognize specific preselected targets |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
US5874306A (en) | 1996-12-12 | 1999-02-23 | The Regents Of The University Of California | Culturing human pancreatic endocrine cells in medium containing extracellular matrix from human bladder carcinoma cells |
EP0988385A2 (en) | 1997-01-21 | 2000-03-29 | Human Genome Sciences | Tace-like and matrilysin-like polypeptides |
US6177076B1 (en) | 1997-12-09 | 2001-01-23 | Thomas Jefferson University | Method of treating bladder cancer with wild type vaccinia virus |
US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
US6165737A (en) | 1998-04-16 | 2000-12-26 | The University Of Texas System Board Of Regents | DNA fragmentation factor involved in apoptosis |
US6284879B1 (en) | 1998-04-16 | 2001-09-04 | The General Hospital Corporation | Transport associated protein splice variants |
JP2002512203A (ja) | 1998-04-17 | 2002-04-23 | ザ ユニバーシティ オブ バーモント アンド ステイト アグリカルチュラル カレッジ | 疾患における代謝的相互作用に関連する方法および製品 |
EP1077723A1 (en) | 1998-05-18 | 2001-02-28 | Applied Research Systems ARS Holding N.V. | Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions |
US7485293B1 (en) | 1999-02-18 | 2009-02-03 | Faustman Denise L | Method for inhibiting transplant rejection |
US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
JP3589912B2 (ja) * | 1999-09-03 | 2004-11-17 | 泰久 福井 | ホスファチジルイノシトール−3,4−二リン酸を認識するモノクローナル抗体 |
EP1257282A4 (en) | 1999-12-06 | 2003-05-02 | Gen Hospital Corp | PANCREATIC STEM CELLS AND THEIR USE IN TRANSPLANTATION |
JP2004500063A (ja) | 1999-12-16 | 2004-01-08 | アムジェン インコーポレイテッド | Tnfr/opg様分子およびその使用 |
US6414218B1 (en) | 2000-01-18 | 2002-07-02 | The General Hospital Corporation | Mouse model for rheumatoid arthritis |
AU2001266604A1 (en) | 2000-05-26 | 2001-12-11 | Smith Kline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
CA2424004A1 (en) | 2000-09-26 | 2002-04-04 | Roger William Hospital | Recombinant bcg vaccines for the prevention and treatment of cancer |
US20040031066A9 (en) | 2001-01-18 | 2004-02-12 | Faustman Denise L. | Mouse model for rheumatoid arthritis |
US7582313B2 (en) | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
WO2004045376A2 (en) | 2002-11-15 | 2004-06-03 | The General Hospital Corporation | Screening methods to identify treatments for autoimmune disease |
EP1687411B1 (en) | 2003-09-26 | 2015-05-06 | The Regents Of The University Of Michigan | Hematopoietic stem cell identification and isolation |
EP1688433A4 (en) | 2003-10-09 | 2008-06-04 | Kyowa Hakko Kogyo Kk | ANTIBODY COMPOSITION SPECIFICALLY INDUCING GANGLIOSIDE GM2 |
US8563308B2 (en) | 2004-03-10 | 2013-10-22 | The Rockefeller University | Culture-expanded T suppressor cells and methods of use thereof |
EP2295588B1 (en) | 2004-05-27 | 2018-03-07 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses thefor |
CN101084014A (zh) | 2004-10-08 | 2007-12-05 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
US20080102054A1 (en) | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
US9081017B2 (en) | 2005-04-11 | 2015-07-14 | Cambridge Enterprise Limited | Methods for identifying modulators of tumor necrosis factor receptors |
JPWO2008090960A1 (ja) | 2007-01-24 | 2010-05-20 | 協和発酵キリン株式会社 | ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物 |
WO2008157394A2 (en) | 2007-06-13 | 2008-12-24 | La Jolla Institute For Allergy And Immunology | Regulatory t cells and methods of making and using same |
WO2009012488A1 (en) | 2007-07-19 | 2009-01-22 | Duke University | Assay for human anti-egrf variant iii antibodies |
WO2009129538A2 (en) * | 2008-04-18 | 2009-10-22 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
AU2010237046B2 (en) | 2009-04-17 | 2015-06-04 | New York University | Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof |
WO2010124259A1 (en) | 2009-04-24 | 2010-10-28 | Centre Hospitalier Universitaire Sainte-Justine | Allosteramers for tnf receptors and uses thereof |
KR20120005460A (ko) * | 2009-04-28 | 2012-01-16 | 베링거 인겔하임 인터내셔날 게엠베하 | Pkc-세타 억제제를 사용하는 면역학적 장애의 생체외 치료 |
US8530392B2 (en) | 2009-05-13 | 2013-09-10 | Shionogi & Co., Ltd. | Test agent for visceral obesity and use thereof |
EP2542577A1 (en) | 2010-03-01 | 2013-01-09 | Lostam Biopharmaceuticals Ltd | Improved therapeutic antibodies against flagellated pseudomonas aeruginosa |
EP3260470A1 (en) | 2010-03-05 | 2017-12-27 | The John Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
US20130064831A1 (en) | 2010-05-17 | 2013-03-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
CA2810465C (en) | 2010-09-16 | 2018-10-02 | Baliopharm Ag | Anti-hutnfr1 antibody |
US20140121123A1 (en) | 2010-10-29 | 2014-05-01 | Kevin Caili Wang | Methods for diversifying antibodies, antibodies derived therefrom and uses thereof |
EP2468764A1 (en) | 2010-12-24 | 2012-06-27 | Rijksuniversiteit te Groningen | TNF family ligand variants |
WO2012122464A1 (en) * | 2011-03-10 | 2012-09-13 | New York University | Methods and compositions for modulating tnf/tnfr signaling |
GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
US20150110794A1 (en) | 2012-04-30 | 2015-04-23 | Cell Signaling Technology, Inc. | Anti-Human Cytomegalovirus Antibodies And Use Thereof |
JP5922845B2 (ja) | 2012-07-18 | 2016-05-24 | 京セラ株式会社 | セルラ通信システムにおける装置間通信の干渉管理 |
EP3936137A1 (en) | 2013-02-07 | 2022-01-12 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
JP6682498B2 (ja) | 2014-03-24 | 2020-04-15 | キャンサー・リサーチ・テクノロジー・リミテッドCancer Research Technology Limited | アゴニストまたはアンタゴニスト性を誘発する修飾されたIgG2ドメインを含む修飾された抗体及びその使用 |
JP6654187B2 (ja) | 2014-08-12 | 2020-02-26 | アリゲーター・バイオサイエンス・アーベー | 抗cd40抗体を用いた併用療法 |
US9172855B1 (en) | 2014-08-28 | 2015-10-27 | Avigilon Corporation | Pendant housing for a camera |
AU2016263198C1 (en) | 2015-05-15 | 2023-10-05 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
WO2017040312A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
WO2017083525A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
KR20240095471A (ko) | 2016-05-13 | 2024-06-25 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
KR102554331B1 (ko) | 2016-08-12 | 2023-07-10 | 얀센 바이오테크 인코포레이티드 | 향상된 효능적 활성을 갖는 Fc 조작된 항-TNFR 수퍼패밀리 구성원 항체 및 그의 사용 방법 |
CN110036031A (zh) | 2016-09-29 | 2019-07-19 | 美国安进公司 | 低粘度抗原结合蛋白及其制备方法 |
JP7054209B2 (ja) | 2016-11-21 | 2022-04-13 | 国立研究開発法人医薬基盤・健康・栄養研究所 | エピトープ均質化抗体パネル、ならびにその作製方法および利用 |
WO2018115003A2 (en) | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
WO2019094559A2 (en) | 2017-11-09 | 2019-05-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
US20210340268A1 (en) | 2018-08-20 | 2021-11-04 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
-
2014
- 2014-02-06 EP EP21175520.2A patent/EP3936137A1/en active Pending
- 2014-02-06 WO PCT/US2014/015101 patent/WO2014124134A1/en active Application Filing
- 2014-02-06 US US14/764,325 patent/US9821010B2/en active Active
- 2014-02-06 EP EP14748807.6A patent/EP2953634B1/en active Active
- 2014-02-06 ES ES14748807T patent/ES2885423T3/es active Active
- 2014-02-06 PL PL14748807T patent/PL2953634T3/pl unknown
- 2014-02-06 DK DK14748807.6T patent/DK2953634T3/da active
- 2014-02-06 PT PT147488076T patent/PT2953634T/pt unknown
- 2014-02-06 JP JP2015557068A patent/JP6367836B2/ja active Active
-
2017
- 2017-11-20 US US15/817,713 patent/US10765700B2/en active Active
-
2018
- 2018-07-05 JP JP2018127922A patent/JP6808688B2/ja active Active
-
2020
- 2020-08-06 US US16/986,755 patent/US11844814B2/en active Active
- 2020-12-09 JP JP2020204143A patent/JP7257374B2/ja active Active
-
2021
- 2021-08-25 HR HRP20211353TT patent/HRP20211353T1/hr unknown
-
2022
- 2022-12-23 JP JP2022207092A patent/JP2023040077A/ja active Pending
-
2023
- 2023-12-14 US US18/540,207 patent/US20240216431A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016509009A (ja) | 2016-03-24 |
EP2953634A4 (en) | 2016-08-17 |
DK2953634T3 (da) | 2021-08-30 |
US20150366909A1 (en) | 2015-12-24 |
EP2953634B1 (en) | 2021-05-26 |
EP2953634A1 (en) | 2015-12-16 |
PL2953634T3 (pl) | 2021-11-22 |
US20240216431A1 (en) | 2024-07-04 |
WO2014124134A1 (en) | 2014-08-14 |
JP2021050225A (ja) | 2021-04-01 |
PT2953634T (pt) | 2021-09-02 |
JP6808688B2 (ja) | 2021-01-06 |
ES2885423T3 (es) | 2021-12-13 |
JP2023040077A (ja) | 2023-03-22 |
US11844814B2 (en) | 2023-12-19 |
EP3936137A1 (en) | 2022-01-12 |
US9821010B2 (en) | 2017-11-21 |
JP6367836B2 (ja) | 2018-08-01 |
JP7257374B2 (ja) | 2023-04-13 |
US10765700B2 (en) | 2020-09-08 |
US20200368282A1 (en) | 2020-11-26 |
US20180161370A1 (en) | 2018-06-14 |
JP2018168183A (ja) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211353T1 (hr) | Postupci za ekspanziju ili depleciju regulacijskih t-stanica | |
HRP20211058T1 (hr) | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 | |
WO2016191246A3 (en) | T cell receptor-like antibodies specific for a prame peptide | |
HRP20231281T1 (hr) | Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom | |
PH12019500603A1 (en) | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof | |
HRP20160212T1 (hr) | Antitijela za terapiju kancera koji eksprimira klaudin 6 | |
CY1122302T1 (el) | Νεα anti-cd38 αντισωματα για τη θεραπευτικη αγωγη καρκινου | |
JP2013517487A5 (hr) | ||
RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
JP2017048240A5 (hr) | ||
JP2021502104A5 (hr) | ||
JP2013227339A5 (hr) | ||
JP2017535257A5 (hr) | ||
JP2020515235A5 (hr) | ||
JP2020503870A5 (hr) | ||
FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
JP2015163068A5 (hr) | ||
RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
JP2016521692A5 (hr) | ||
JP2017514461A5 (hr) | ||
JP2013506428A5 (hr) | ||
JP2015517300A5 (hr) | ||
WO2016058148A1 (zh) | 抗butyrophilin-3人源化抗体及其使用 |